Cell-Mediated Immune Response after COVID 19 Vaccination in Patients with Inflammatory Bowel Disease

  1. Freddy Caldera
  2. Francis A. Farraye
  3. Brian M. Necela
  4. Davitte Cogen
  5. Sumona Saha
  6. Arnold Wald
  7. Nader D. Daoud
  8. Kelly Chun
  9. Ian Grimes
  10. Megan Lutz
  11. Melanie D. Swift
  12. Abinash Virk
  13. Adil E. Bharucha
  14. Tushar C. Patel
  15. Gregory J. Gores
  16. Saranya Chumsri
  17. Mary S. Hayney
  18. Keith L. Knutson
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Introduction

Most patients with IBD mount an antibody response to mRNA COVID-19 vaccines, but few studies have evaluated the cell mediated immune response (CMIR).

Methods

We performed a prospective study (HERCULES) to evaluate CMIR among patients with IBD and healthy controls (HC) after completion of the primary series of mRNA COVID-19 vaccines.

Results

One hundred 158 patients with IBD and 20 HC were enrolled. The majority (89%) of IBD patients developed a CMIR which was not different than HC (94%, p=0.6667). There was no significant difference (p=0.5488) in CMIR response between those not immunosuppressed (median 255 Spike T cells/million PBMC, IQR 146, 958) and immunosuppressed (median 377, IQR 123, 1440). There was also no correlation between antibody responses and CMIR (p=0.5215)

Discussion

Most patients with IBD achieved CMIR to a COVID-19 vaccine. Future studies are needed evaluating sustained CMIR and clinical outcomes.

Related articles

Related articles are currently not available for this article.